Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more
Regeneron Pharmaceuticals Inc (REGN) - Net Assets
Latest net assets as of December 2025: $31.26 Billion USD
Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) has net assets worth $31.26 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.56 Billion) and total liabilities ($9.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.26 Billion |
| % of Total Assets | 77.07% |
| Annual Growth Rate | 25.14% |
| 5-Year Change | 66.54% |
| 10-Year Change | 602.52% |
| Growth Volatility | 130.86 |
Regeneron Pharmaceuticals Inc - Net Assets Trend (1990–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Regeneron Pharmaceuticals Inc (1990–2025)
The table below shows the annual net assets of Regeneron Pharmaceuticals Inc from 1990 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $31.26 Billion | +6.48% |
| 2024-12-31 | $29.35 Billion | +13.02% |
| 2023-12-31 | $25.97 Billion | +14.60% |
| 2022-12-31 | $22.66 Billion | +20.75% |
| 2021-12-31 | $18.77 Billion | +70.23% |
| 2020-12-31 | $11.03 Billion | -0.58% |
| 2019-12-31 | $11.09 Billion | +26.63% |
| 2018-12-31 | $8.76 Billion | +42.53% |
| 2017-12-31 | $6.14 Billion | +38.09% |
| 2016-12-31 | $4.45 Billion | +21.74% |
| 2015-12-31 | $3.65 Billion | +43.76% |
| 2014-12-31 | $2.54 Billion | +30.24% |
| 2013-12-31 | $1.95 Billion | +56.74% |
| 2012-12-31 | $1.25 Billion | +156.39% |
| 2011-12-31 | $485.73 Million | -7.97% |
| 2010-12-31 | $527.82 Million | +33.03% |
| 2009-12-31 | $396.76 Million | -5.27% |
| 2008-12-31 | $418.85 Million | -9.00% |
| 2007-12-31 | $460.27 Million | +112.47% |
| 2006-12-31 | $216.62 Million | +90.02% |
| 2005-12-31 | $114.00 Million | -37.55% |
| 2004-12-31 | $182.54 Million | +32.62% |
| 2003-12-31 | $137.64 Million | -5.71% |
| 2002-12-31 | $145.98 Million | -45.19% |
| 2001-12-31 | $266.36 Million | +46.24% |
| 2000-12-31 | $182.13 Million | +66.33% |
| 1999-12-31 | $109.50 Million | -16.54% |
| 1998-12-31 | $131.20 Million | -5.54% |
| 1997-12-31 | $138.90 Million | +29.93% |
| 1996-12-31 | $106.90 Million | +57.44% |
| 1995-12-31 | $67.90 Million | +1.19% |
| 1994-12-31 | $67.10 Million | -31.81% |
| 1993-12-31 | $98.40 Million | +12.84% |
| 1992-12-31 | $87.20 Million | -17.89% |
| 1991-12-31 | $106.20 Million | +770.49% |
| 1990-12-31 | $12.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regeneron Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3580410000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $35.80 Billion | 114.53% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $77.50 Million | 0.25% |
| Total Equity | $31.26 Billion | 100.00% |
Regeneron Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Regeneron Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Johnson Controls International PLC
NYSE:JCI
|
$75.00 Billion |
|
Safran SA
PINK:SAFRF
|
$75.30 Billion |
|
Brookfield Corp
NYSE:BN
|
$75.33 Billion |
|
O’Reilly Automotive Inc
NASDAQ:ORLY
|
$75.46 Billion |
|
Emerson Electric Company
NYSE:EMR
|
$74.51 Billion |
|
Cummins Inc
NYSE:CMI
|
$74.50 Billion |
|
Marriott International Inc
NASDAQ:MAR
|
$74.24 Billion |
|
The Williams Companies, Inc.
SA:W1MB34
|
$74.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regeneron Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,353,600,000 to 31,256,900,000, a change of 1,903,300,000 (6.5%).
- Net income of 4,504,900,000 contributed positively to equity growth.
- Dividend payments of 370,300,000 reduced retained earnings.
- Share repurchases of 3,438,600,000 reduced equity.
- New share issuances of 635,900,000 increased equity.
- Other comprehensive income increased equity by 85,400,000.
- Other factors increased equity by 486,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.50 Billion | +14.41% |
| Dividends Paid | $370.30 Million | -1.18% |
| Share Repurchases | $3.44 Billion | -11.0% |
| Share Issuances | $635.90 Million | +2.03% |
| Other Comprehensive Income | $85.40 Million | +0.27% |
| Other Changes | $486.00 Million | +1.55% |
| Total Change | $- | 6.48% |
Book Value vs Market Value Analysis
This analysis compares Regeneron Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 953.21x to 2.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.79 | $756.91 | x |
| 1991-12-31 | $6.84 | $756.91 | x |
| 1992-12-31 | $5.66 | $756.91 | x |
| 1993-12-31 | $5.94 | $756.91 | x |
| 1994-12-31 | $3.54 | $756.91 | x |
| 1995-12-31 | $3.44 | $756.91 | x |
| 1996-12-31 | $4.37 | $756.91 | x |
| 1997-12-31 | $4.79 | $756.91 | x |
| 1998-12-31 | $4.23 | $756.91 | x |
| 1999-12-31 | $3.48 | $756.91 | x |
| 2000-12-31 | $5.18 | $756.91 | x |
| 2001-12-31 | $6.33 | $756.91 | x |
| 2002-12-31 | $3.32 | $756.91 | x |
| 2003-12-31 | $2.73 | $756.91 | x |
| 2004-12-31 | $3.25 | $756.91 | x |
| 2005-12-31 | $2.04 | $756.91 | x |
| 2006-12-31 | $3.74 | $756.91 | x |
| 2007-12-31 | $6.94 | $756.91 | x |
| 2008-12-31 | $5.31 | $756.91 | x |
| 2009-12-31 | $4.97 | $756.91 | x |
| 2010-12-31 | $6.36 | $756.91 | x |
| 2011-12-31 | $5.36 | $756.91 | x |
| 2012-12-31 | $10.79 | $756.91 | x |
| 2013-12-31 | $17.54 | $756.91 | x |
| 2014-12-31 | $22.41 | $756.91 | x |
| 2015-12-31 | $31.72 | $756.91 | x |
| 2016-12-31 | $38.26 | $756.91 | x |
| 2017-12-31 | $53.01 | $756.91 | x |
| 2018-12-31 | $76.28 | $756.91 | x |
| 2019-12-31 | $96.77 | $756.91 | x |
| 2020-12-31 | $95.79 | $756.91 | x |
| 2021-12-31 | $167.28 | $756.91 | x |
| 2022-12-31 | $199.68 | $756.91 | x |
| 2023-12-31 | $228.44 | $756.91 | x |
| 2024-12-31 | $255.03 | $756.91 | x |
| 2025-12-31 | $287.82 | $756.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regeneron Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.41%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.41%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.30x
- Recent ROE (14.41%) is above the historical average (-9.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -27.05% | -66.00% | 0.20x | 2.08x | $-4.52 Million |
| 1991 | -4.24% | -61.64% | 0.06x | 1.07x | $-15.12 Million |
| 1992 | -21.90% | -166.09% | 0.12x | 1.12x | $-27.82 Million |
| 1993 | -40.55% | -376.42% | 0.09x | 1.20x | $-49.74 Million |
| 1994 | -45.75% | -132.33% | 0.25x | 1.40x | $-37.41 Million |
| 1995 | -34.61% | -85.77% | 0.29x | 1.38x | $-30.29 Million |
| 1996 | -30.31% | -134.44% | 0.18x | 1.29x | $-43.09 Million |
| 1997 | -8.35% | -35.05% | 0.20x | 1.21x | $-25.49 Million |
| 1998 | -6.55% | -22.51% | 0.24x | 1.20x | $-21.72 Million |
| 1999 | -21.10% | -66.96% | 0.25x | 1.25x | $-34.05 Million |
| 2000 | -12.75% | -39.16% | 0.28x | 1.14x | $-41.43 Million |
| 2001 | -28.60% | -346.70% | 0.04x | 1.86x | $-102.82 Million |
| 2002 | -85.20% | -565.66% | 0.06x | 2.68x | $-138.98 Million |
| 2003 | -78.07% | -186.89% | 0.12x | 3.48x | $-121.22 Million |
| 2004 | 22.84% | 23.96% | 0.37x | 2.59x | $23.44 Million |
| 2005 | -83.72% | -144.19% | 0.16x | 3.71x | $-106.85 Million |
| 2006 | -47.24% | -161.30% | 0.11x | 2.70x | $-124.00 Million |
| 2007 | -22.94% | -84.46% | 0.13x | 2.03x | $-151.63 Million |
| 2008 | -19.75% | -34.69% | 0.36x | 1.60x | $-124.60 Million |
| 2009 | -17.10% | -17.88% | 0.51x | 1.87x | $-107.51 Million |
| 2010 | -19.79% | -22.76% | 0.42x | 2.06x | $-157.25 Million |
| 2011 | -45.65% | -49.74% | 0.34x | 2.72x | $-270.33 Million |
| 2012 | 60.24% | 54.43% | 0.66x | 1.67x | $625.73 Million |
| 2013 | 21.74% | 20.16% | 0.71x | 1.51x | $229.15 Million |
| 2014 | 13.69% | 12.34% | 0.73x | 1.52x | $93.84 Million |
| 2015 | 17.40% | 15.50% | 0.73x | 1.53x | $270.57 Million |
| 2016 | 20.13% | 18.42% | 0.70x | 1.57x | $450.60 Million |
| 2017 | 19.51% | 20.41% | 0.67x | 1.43x | $584.10 Million |
| 2018 | 27.91% | 36.42% | 0.57x | 1.34x | $1.57 Billion |
| 2019 | 19.08% | 26.91% | 0.53x | 1.34x | $1.01 Billion |
| 2020 | 31.86% | 41.35% | 0.50x | 1.56x | $2.41 Billion |
| 2021 | 43.03% | 50.25% | 0.63x | 1.36x | $6.20 Billion |
| 2022 | 19.14% | 35.64% | 0.42x | 1.29x | $2.07 Billion |
| 2023 | 15.22% | 30.14% | 0.40x | 1.27x | $1.36 Billion |
| 2024 | 15.03% | 31.07% | 0.38x | 1.29x | $1.48 Billion |
| 2025 | 14.41% | 31.41% | 0.35x | 1.30x | $1.38 Billion |
Industry Comparison
This section compares Regeneron Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc (REGN) | $31.26 Billion | -27.05% | 0.30x | $74.58 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |